KDR and cancer: Sorafenib is a multi-target TKI, approved since 2007 for first-line treatment of HCC, which can block the RAS, VEGFR, platelet-derived growth factor receptor (PDGFR), fms related tyrosine kinase 3 (FLT3), and KIT kinases, inducing apoptosis and blocking cell proliferation, migration, and cancer angiogenesis (96).